MARKSANS329.00

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,909 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MARKSANS
FY26
GRANULES
FY26
METROPOLIS
FY26
PARKHOSPS
FY26
Peer
Median
Valuation — at last close
P/E35.68×36.64×64.74×41.19×41.19× -13%
P/B4.88×4.37×8.09×5.81×5.81× -16%
EV/EBITDA23.81×19.13×30.33×27.49×27.49× -13%
Market Cap₹14,909 Cr₹22,215 Cr₹12,336 Cr₹12,224 Cr₹12,336 Cr +21%
Growth
Revenue CAGR 3Y16.80%5.95%12.75%9.35% +80%
Revenue CAGR 5Y16.48%10.63%10.52%10.57% +56%
Net Income CAGR 3Y16.55%4.82%10.06%7.44% +122%
Revenue YoY (latest Q)35.61%22.04%16.62%19.33% +84%
Net Income YoY (latest Q)173.89%59.77%25.72%42.75% +307%
Profitability
EBITDA Margin20.36%22.09%24.36%26.46%24.36% -16%
Net Income Margin14.23%11.09%11.62%16.29%11.62% +22%
Return on Common Equity13.69%11.70%12.46%12.27%12.27% +12%
Return on Capital Employed15.06%15.80%14.81%16.72%15.80% -5%
Return on Assets10.88%7.71%8.94%9.72%8.94% +22%
Credit & Quality
Total Debt/Equity0.01×0.26×0.01×0.11×0.11× -91%
Interest Coverage20.81×7.77×10.88×6.48×7.77× +168%
Scale — latest FY
Revenue / Total Income₹2,951 Cr₹5,366 Cr₹1,646 Cr₹1,679 Cr₹1,679 Cr +76%
Net Income₹420 Cr₹595 Cr₹191 Cr₹274 Cr₹274 Cr +54%
Total Assets₹3,861 Cr₹7,720 Cr₹2,138 Cr₹2,813 Cr₹2,813 Cr +37%
EPS₹9.22₹24.47₹9.19₹6.87₹9.19 +0%
Book Value per Share₹67.36₹205.21₹73.53₹48.72₹73.53 -8%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.